DVHGF Stock Devonian Health Group (DVHGF, $0.07) dropped -60.5% over the last 3 months. Expect a Downtrend continuation
at Tickeron.com
Loading...
Devonian Health Group (DVHGF, $0.07) lost over the last three months. By comparison, the broader Biotechnology Industry returned 3 over the same period. A.I.dvisor analyzed 783 stocks in the Biotechnology Industry over the last three months, and found that of them (6) exhibited an Uptrend while of them (3) experienced a Downtrend. A.I.dvisor found 66 similar cases when DVHGF's price dropped within three months. In out of those 66 cases, DVHGF's price went down during the following month. Based on these historical data, A.I. thinks the odds of a Downtrend continuation for DVHGF are
DVHGF in upward trend: price rose above 50-day moving average on November 28, 2025
DVHGF moved above its 50-day moving average on November 28, 2025 date and that indicates a change from a downward trend to an upward trend. In of 7 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The 10-day moving average for DVHGF crossed bullishly above the 50-day moving average on November 28, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 7 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.866) is normal, around the industry mean (27.312). P/E Ratio (0.000) is within average values for comparable stocks, (52.442). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.886). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (0.475) is also within normal values, averaging (321.020).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. DVHGF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DVHGF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Advertisement
General Information
Industry Biotechnology